Insider buying last 90 days
No open-market insider purchases were filed for RXRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RXRX insider filing, plotted on the chart in Gekko.Open RXRX in Gekko
NASDAQ: RXRX
Recursion Pharmaceuticals (RXRX) Stock Analysis & Forecast
Oct 12 close
$4.01−0.35 (−8.0%)
Gekko Brief
AI summaryOct 12 closeRecursion shares fell to $4.01 this week, registering an 8% drop in the latest session and continuing a decline from $4.63 and $4.5750 earlier in the period. No new clinical, regulatory or deal news accompanied the move; the only company-specific items were proposed insider share sales by directors Robert Hershberg and Blake C. Borgeson, each tied to prior option exercises and filed for routine disposal.
Despite the pullback, the close of $4.01 remains above both the 50-day average of $3.58 and the 200-day average of $3.57, with the 50-day above the 200-day. The GekkoIndex sits at 55.2, in the Neutral zone, up 12.4 over the past five readings. Price sits 19.6% below the Gekko Fair Value of $4.99.
The next earnings date falls on 4 November 2026, before the open, within the typical 20-trading-day holding window and following a last reported EPS of -0.25 against a -0.24 estimate, with a -3.9% reaction and an average absolute move of 8.7% historically. No insider, Congress or unusual options activity is recorded in the respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -4.3% across 5 years, rising in 2 of them. Five analysts cover the stock, with 2 buy and 3 hold ratings and a consensus target of $7.22, implying 80% upside under that consensus.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Recursion Pharmaceuticals price vs fair value
Close $4.01200-day averageGekko Fair Value $4.99
Recursion Pharmaceuticals quick facts
- Market cap
- $2.10B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.00
- Revenue, TTM
- $54.86M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.03
- Volume
- 23.72M avg 30.02M
- 1-year return
- −32.1%
- Typical daily move
- ±10.3%
- Typical 20-day move
- ±13.6%
- 50-day average
- $3.58
- 200-day average
- $3.57
- Next earnings
- Nov 4 before open
- Shares outstanding
- 535.3M
Recursion Pharmaceuticals swing-trade checklist
Recursion Pharmaceuticals scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $4.01 is above the 50-day ($3.58) and 200-day ($3.57) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.2, Neutral
Reading 55.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
19.6% below
Price is 19.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.3% on average
From this point in the calendar, the next 20 trading days averaged −4.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Recursion Pharmaceuticals stock chart and price history
Recursion Pharmaceuticals closed at $4.01 on Oct 12, 2026, −32.1% over the past year, inside a 52-week range of $2.77 to $7.18.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +25.3%
- 3 months
- +20.1%
- 6 months
- +17.3%
- 1 year
- −32.1%
The full RXRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RXRX in Gekko
Follow Recursion Pharmaceuticals through every session
Put RXRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RXRX in GekkoFree for 7 days. No credit card required.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a biotech business that has not yet moved past the testing stage into selling finished drugs. It brings together tools from biology, chemistry, automation, data science, and engineering in an effort to map out how diseases work at a cellular level, and this blended, tech-driven method of searching for new medicines is what sets the company apart.
Its research is built around a lineup of drug candidates at various points in development. A handful have entered human trials, targeting conditions like cerebral cavernous malformation, GM2 gangliosidosis, neurofibromatosis type 2, and familial adenomatous polyposis, while a larger group of candidates is still being studied before reaching that stage, covering areas such as inflammatory disease, ovarian and liver cancers, lung cancer, and other tumor-related conditions. To support this work, Recursion has entered into partnerships with outside organizations, among them Bayer AG, Takeda Pharmaceutical Company Limited, the University of Utah Research Foundation, the Ohio State Innovation Foundation, and Chromaderm, Inc.
Recursion Pharmaceuticals began operations in 2013 and runs out of Salt Lake City, Utah. Investors can find its stock listed on the NASDAQ under the ticker RXRX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- recursion.com
Recursion Pharmaceuticals GekkoIndex: the smart money zone
Recursion Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.2, in the Neutral zone, up 12.4 points over five sessions.
55.2Neutral
Up 12.4 points over five sessions, from the Distribution zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | +8.2% | +11.5% | ||
| Accumulation | 294 | +1.1% | +1.8% | ||
| Neutral (current zone) | 328 | −1.4% | −4.4% | ||
| Distribution | 23 | −6.8% | −20.4% | ||
| Selling | 1 | Too few readings yet | |||
Average RXRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RXRX price, zone by zone.Track RXRX in Gekko
Is Recursion Pharmaceuticals stock overvalued? Gekko Fair Value
Recursion Pharmaceuticals trades 19.6% below Gekko Fair Value of $4.99, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Recursion Pharmaceuticals shares are worth, recalculated every trading day.
$4.99
Gekko Fair Value, Oct 10, 2026
19.6% Undervalued
At the end of Aug 2026 the price was 41.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open RXRX in Gekko
Recursion Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Recursion Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RXRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RXRX, plotted on the chart in Gekko.Open RXRX in Gekko
Recursion Pharmaceuticals earnings: next date and track record
Recursion Pharmaceuticals reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- −$0.22
- Revenue estimate
- $12.98M
3 of 8reports beat the EPS estimate
±8.7%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Recursion reported 5 clinical-stage programs including REC-4881 in FAP, describing it as their most promising clinical data historically in a ~$10B TAM disease with no approved therapy. Partnerships with Sanofi and Roche/Genentech generated over $500M in realized inflows. A new milestone was announced: Genentech advanced a neuroscience target into joint early discovery. REC-7735 received IND clearance to enter clinic later this year.
- Guidance
- Additional Phase II REC-4881 data will be presented at CGA-IGC Conference later this year, with FDA interaction updates forthcoming. REC-7735 expected to enter the clinic later this year. Management signaled continued pipeline maturation across internal and partnered programs.
- Risks flagged
- Limited regulatory precedent in FAP and ongoing FDA engagement; competitive environment in oncology and PI3K-targeted therapeutics; execution risk in translating AI capabilities into repeatable drug discovery outcomes; patient enrollment/diagnostic requirements for biomarker-selected trials; reliance on proprietary data generation and specialized infrastructure that require continued investment and operational competence.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.25 est −$0.24 | $7.30M est $10.97M | −3.9% |
| May 6, 2026 | −$0.22 est −$0.26 | $6.30M est $15.78M | −3.0% |
| Feb 25, 2026 | −$0.21 est −$0.28 | $35.35M est $24.54M | +6.8% |
| Nov 5, 2025 | −$0.36 est −$0.38 | $5.18M est $24.56M | −7.6% |
| Aug 5, 2025 | −$0.41 est −$0.35 | $19.10M est $19.93M | −5.5% |
| May 5, 2025 | −$0.50 est −$0.44 | $14.75M est $13.96M | −27.0% |
| Feb 28, 2025 | −$0.53 est −$0.44 | $4.51M est $19.04M | −14.1% |
| Nov 6, 2024 | −$0.34 est −$0.33 | $26.08M est $18.17M | +1.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Recursion Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Recursion Pharmaceuticals is $7.22, +80.0% from the last close, from 5 firms rating the stock in the last 90 days.
$7.22consensus 12-month target, +80.0% from the last close
Now $4.01Avg $7.22
Low $5.30High $8
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | Bank of America Securities | — | — |
| Sep 15 | J.P. Morgan | — | — |
| Aug 17 | Morgan Stanley | $5.30 | +32.2% |
| Aug 12 | Bank of America Securities | $6 | +49.6% |
| Aug 7 | Bank of America Securities | $6 | +49.6% |
−4.4%average 20-day move after past Neutral readings
−4.3%average move over the next 20 trading days in the last 5 years
±10.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Recursion Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Recursion Pharmaceuticals averaged −4.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.4% | 3 of 5 |
| Next 10 trading days | +0.3% | 3 of 5 |
| Next 15 trading days | −1.3% | 3 of 5 |
| Next 20 trading days | −4.3% | 2 of 5 |
| Next 30 trading days | −11.4% | 0 of 5 |
For scale, RXRX’s typical 20-trading-day move in either direction is about 13.6%.
Recursion Pharmaceuticals market cap and key statistics
Recursion Pharmaceuticals’s market cap is $2.10B and revenue of $54.86M over the last twelve months.
Valuation
- Market cap
- $2.10B
- EPS, TTM
- −$1.00
- Gekko Fair Value
- $4.99
Trading
- Volume
- 23.72M
- Avg volume, 20 days
- 30.02M
- 52-week high
- $7.18
- 52-week low
- $2.77
- Shares outstanding
- 535.3M
Financials
- Revenue, TTM
- $54.86M
- Profit margin
- 0%
- Return on equity
- -56.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.03
- Typical daily move
- ±10.3%
- Typical 20-day move
- ±13.6%
Recursion Pharmaceuticals stock news this week
Coverage of Recursion Pharmaceuticals this week reads negative: 0 positive, 3 neutral and 3 negative headlines.
- Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research, Oct 12
- Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3% – What’s Next?Defense World, Oct 8
- Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP)Defense World, Oct 8
- A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX).Stock Titan, Oct 8
- Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each.Stock Titan, Oct 7
- 25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg.Stock Titan, Oct 7
Recursion Pharmaceuticals peers
Recursion Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Recursion Pharmaceuticals stock FAQ
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.10B at the Oct 12, 2026 close of $4.01, with 535.3M shares outstanding.
What is the Recursion Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Recursion Pharmaceuticals is $7.22, +80.0% from the last close. Of the 5 firms that rated the stock in the last 90 days, 2 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Recursion Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Recursion Pharmaceuticals is undervalued: the Oct 12, 2026 close of $4.01 is 19.6% below Gekko Fair Value of $4.99. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Recursion Pharmaceuticals report earnings next?
Recursion Pharmaceuticals is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of −$0.22 per share on revenue of $12.98M. Recursion Pharmaceuticals beat the earnings estimate in 3 of its last 8 reports, moving 8.7% on average across the report.
What is Recursion Pharmaceuticals’s 52-week high and low?
Recursion Pharmaceuticals’s 52-week high is $7.18 and its 52-week low is $2.77; it closed at $4.01 on Oct 12, 2026, −32.1% over the past year. Over the last five years the shares peaked at $21.19 on Dec 7, 2021.
Is Recursion Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 1 as mixed (gekkoindex) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Recursion Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.